Article
03 November 2025 - by Gabriela Dieguez, Charmaine Girdish, Prachi Bhatt
Multiple sclerosis costs employers nationwide more than $1 billion annually, but we estimate there is an opportunity to reduce disability-related claim costs by up to 30%.
Article
02 June 2025 - by Hanaa Siddiqi, Gabriela Dieguez, Charmaine Girdish, Siyi Lu, Carol Bazell
Among kidney transplants in the United States, 64% of procedures were paid for by Medicare, and 90% of patients received induction therapy, according to our analysis for Sanofi U.S.
Article
18 March 2025 - by Prachi Bhatt, Gabriela Dieguez
With the 2026 implementation of maximum fair prices on selected anticoagulants, we modeled potential effects on rates of treatment for Medicare Part D beneficiaries.
Article
05 September 2024 - by Katherine M. Holcomb, Madeleine Cline, Jake K. Klaisner, Jennifer Carioto, Gabriela Dieguez
We explore the implications of the 2026 maximum fair prices within Medicare price negotiation, part of a paradigm shift in Part D access and cost. 
Article
24 July 2024 - by Gabriela Dieguez, Tyler Engel, James Burke
We examined utilization and reimbursement patterns of COVID-19 tests in the commercially-insured population.
Article
21 December 2023 - by Jennifer Carioto, Gabriela Dieguez, Tushar Makhija
We expect the financial implications of the Inflation Reduction Act to lead to a reassessment of formulary strategies by Medicare Part D plans.
Article
15 February 2022 - by Gabriela Dieguez, Jennifer Carioto
Quantifying the impact of expanding biomarker testing coverage in the commercial and Medicaid markets.
Article
13 July 2021 - by Gabriela Dieguez, Rebecca Smith
Early detection and intervention for patients chronic kidney disease could significantly reduce healthcare costs for Medicare and commercial plans.
Article
04 February 2021 - by Susan Silseth, Gabriela Dieguez, Edwin Jonaitis
This white paper studies the impact of formulary restrictions on “walk-away” rates for commercially insured patients prescribed HIV PrEP. 
Article
19 November 2020 - by Fernando Mesquida, Gabriela Dieguez, Jorge Torres, Romina Santoro
Es conocido que las comorbilidades se relacionan con una alta proporción de fallecimientos relacionados con el COVID-19 pero hasta ahora no había sido posible cuantificar el efecto de las mismas sobre la mortalidad segmentado por edad y género.